Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CHKA | P35790 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1597363 | 0.98 | CA2 (0.59) | CA2CHKAMEN1TP53KMT2A | |
| Formic Acid SCHEMBL7305919 | 0.92 | CA2 (0.53) | CA2CHKAMEN1TP53KMT2A | |
| SCHEMBL3074616 | 0.92 | CA2 (0.64) | CA2CHKAMEN1TP53KMT2A | |
| Hydrochloric Acid SCHEMBL6762954 | 0.90 | CA2 (0.62) | CA2CHKAMEN1TP53KMT2A | |
| Trifluoroacetic Acid SCHEMBL9066267 | 0.87 | CA2 (0.48) | CA2CHKAMEN1TP53KMT2A | |
| SCHEMBL10650643 | 0.86 | CA12 (0.46) | CA2CHKAMEN1TP53KMT2A | |
| SCHEMBL2899860 | 0.85 | MEN1 (0.80) | MEN1TP53KMT2ASMN1; SMN2MAPT | |
| SCHEMBL2561632 | 0.85 | CA2 (0.80) | CA2CHKAMEN1TP53KMT2A | |
| SCHEMBL10665698 | 0.83 | CA2 (0.76) | CA2CHKAMEN1TP53KMT2A | |
| SCHEMBL11741744 | 0.83 | MEN1 (0.85) | MEN1TP53KMT2ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388589-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. | 2024-09-12 | — | — | US | disclosed |
| US-20240140954-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2024-05-02 | — | — | US | disclosed |
| WO-2023205914-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2023-11-02 | — | — | WO | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| EP-3212201-B1 | NUCLEOSIDE KINASE INHIBITORS | BCI PHARMA (FR) | 2022-10-19 | — | — | EP | disclosed |
| US-9951086-B2 | Indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| US-20180105512-A1 | SUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2018-04-19 | — | — | US | disclosed |
| US-20180105512-A1 | SUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2018-04-19 | — | — | US | disclosed |
| EP-2799435-B1 | POLY (ADP-RIBOSE) POLYMERASE INHIBITOR | CHENGDU DIAO PHARMACEUTICAL GROUP CO LTD (CN) | 2018-03-28 | — | — | EP | disclosed |
| WO-2006046031-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005095387-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-10-13 | — | — | WO | disclosed |
| CN-1633420-A | Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors | TORRENT PHARMACEUTICALS LTD (IN) | 2005-06-29 | — | — | CN | disclosed |
| US-6265381-B1 | MORPHOLINOUREA AND RELATED DERIVATIVES OF PENTAFLUOROETHYL PEPTIDES | MERRELL PHARMACEUTICALS, INC. | 2001-07-24 | — | — | US | disclosed |
| US-5714470-A | PENTAFLUORO ALKYL TERMINATED PEPTIDE DERIVATIVES; TREATMENT OF INFLAMMATORY DISEASES, EMPHYSEMA AND CHRONIC BRONCHITIS | MERRELL PHARMACEUTICALS, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| US-5561140-A | IMMUNOSUPPRESSANTS; SIDE EFFECT REDUCTION | ABBOTT LABORATORIES (US) | 1996-10-01 | — | — | US | disclosed |
| US-5530119-A | IMMUNOSUPPRESSANTS | ABBOTT LABORATORIES (US) | 1996-06-25 | — | — | US | disclosed |
| EP-0690713-A1 | SUBSTITUTED ALICYCLIC AMINE-CONTAINING MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994021254-A1 | SUBSTITUTED ALICYCLIC AMINE-CONTAINING MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105512-A1 | SUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | TPSD1, TPSAB1, TMSB4X | CA2 880/4885CHKA 1857/4885MEN1 1290/4885 |
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | SETD2, CARM1, SETDB1 | CA2 2516/4885CHKA 393/4885MEN1 3154/4885 |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | CA2 1982/4885CHKA 208/4885MEN1 3383/4885 |
| US-20240140954-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | CYP11B2, SDHA, CYP3A43 | CA2 3053/4885CHKA 647/4885MEN1 1858/4885 |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | EZH2, HDAC2, SETD2 | CA2 4117/4885CHKA 3056/4885MEN1 2641/4885 |
| US-20250388589-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | CYP4A11, CYP11B1, CYP2D6 | CA2 445/4885CHKA 550/4885MEN1 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.